Essential medicines and access to insulin

We fully support the views expressed in The Lancet Diabetes & Endocrinology’s Editorial¹ about ensuring affordable access to insulin and the proposal to add analogue insulin to the WHO Essential Medicines list. The International Insulin Foundation in its 2011 position statement called for “the universal access for persons with type 1 diabetes to life-saving and life-preserving insulin”.² In 2012, we launched the 100 Campaign, which sets the target of 100% affordability and 100% availability of insulin worldwide by the year 2022 (100 years after the introduction of insulin for people with diabetes). With our focus on improving access to insulin, we were very surprised by the proposal to include analogue insulins on the WHO Model List of Essential Medicines.

Problems with the price and affordability of insulin are not confined to low-income and middle-income countries: the price of insulin in the USA has been attracting attention.³ The main driver of this issue is that analogue insulins are much more expensive than human insulins. detemir insulins are seven to nine times more expensive than human insulins. The main driver of this issue is that analogue insulins are much more expensive than human insulins. detemir insulins are seven to nine times more expensive than human insulins.

Besides cost, we are concerned that, although the current use of analogue insulins is directed towards people with type 1 diabetes, market forces will probably encourage use of analogue insulins by people with type 2 diabetes, leading to an increased economic burden for countries and individuals. The evidence base for the superiority of analogue insulins is also weak. The application to WHO is supported by a systematic review and network meta-analysis⁴ that largely comprised open-label, manufacturer-sponsored studies. As a result, in the submission’s summary tables, all but two studies are described as at serious or very serious risk of bias. Many of the studies compared long-acting analogues with once daily isophane insulin. The systematic review described the benefits of analogues as “probably superior” to isophane insulin with respect to HbA₁c, with the authors noting that the “difference is small” and “no differences are likely to be clinically relevant”; for cost-effectiveness, the results “were inconsistent across studies”.⁴

We therefore agree with the conclusions of the Editorial that access to human insulin is still “despairingly low” for many patients worldwide and that adding more expensive insulins to the WHO model list is not likely to improve this situation.¹ We trust that WHO will reject this application.

The authors are trustees of the International Insulin Foundation (IFF). GG is chair, JSY is vice-chair and treasurer, and ST is secretary of the IFF. SW received lecture fees into research accounts from Novo Nordisk and AstraZeneca. All other authors declare no competing interests.

¹ Geoff Gill, John S Yudkin, Solomon Tesfaye, Maximilian de Courten, Edwin Gale, Ayesha Motala, Kaushik Ramaiya, Nigel Unwin, Sarah Wild

g.gill@liverpool.ac.uk

Lancet Diabetes Endocrinol 2017

Clinical Unit, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK (GG); School of Medicine, University of Liverpool, Liverpool, UK (GG); Institute of Cardiovascular Science, University College London, London, UK (JSY); Department of Diabetes and Endocrinology, Sheffield Teaching Hospitals and University of Sheffield, Sheffield, UK (ST). Centre for Chronic Disease, Victoria University, Melbourne, VIC, Australia (MdC); School of Clinical Sciences, University of Bristol, Bristol, UK (EG); Department of Diabetes and Endocrinology, School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa (AM); Department of Internal Medicine, Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania (KR); MRC Epidemiology Unit, University of Cambridge, Cambridge, UK (N); and Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK (SW)


